Source: Epilepsia  |  Posted 9 years ago

Brimonidine-purite 0.15% and 0.2%, appears to decrease intraocular pressure comparably to brimonidine 0.2% in patients with glaucoma or ocular hypertension.

Jay Katz, MD, of the Brimonidine-Purite Study Group, Wills Eye Hospital, Philadelphia, Pennsylvania, United States headed this 12-month, randomized, multi-center study of the two drugs--with brimonidine-Purite tested at two different concentrations. The group found that brimonidine-Purite 0.15% showed the most favorable safety and tolerability profile and a reduced incidence of allergic conjunctivitis. It also showed a better satisfaction and comfort rating.

There were no statistically significant differences in mean intraocular pressure or mean changes from baseline intraocular pressure (at peak or trough) among groups receiving either drug. Difference in mean intraocular pressure between patients receiving brimonidine-purite-0.15% and those receiving brimonidine-0.2% treatment group was less than 1 mmHg.

The relative percent difference in allergic conjunctivitis was 41% lower in the brimonidine-purite 0.15% group compared with the brimonidine 0.2% group. The comfort and satisfaction rating significantly favored brimonidine-Purite 0.15%, he reports.

In the study, 381 patients were randomly assigned to receive brimonidine-Purite 0.15%, 383 received brimonidine-Purite 0.2%, and 383 received brimonidine 0.2%. All patients received the drugs three times daily, and mean intraocular pressure at baseline was similar in the three treatment groups.

Diurnal intraocular pressure was measured four times daily at baseline, week six, and at three months, six months, and 12 months. Intraocular pressure was also measured twice daily at week two and month nine. Safety was evaluated by adverse events and other ocular and systemic measures.